跳至主要内容
临床试验/NCT04286009
NCT04286009已完成不适用

Pathogenesis and Mechanisms of Mitral Annular Calcification

Mayo Clinic1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2020年7月28日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Mayo Clinic
入组人数
45
试验地点
1
主要终点
Prognostic markers of calcific cardiac valves

研究概览

简要总结

Researchers are testing blood or mitral valve tissue to better understand the reasons why Mitral Annular Calcification (MAC) develops in patients with heart disease.

详细描述

The aim is to test the hypothesis that Endothelial Progenitor Cells osteoblastic phenotype (EPC-OCNs) play a significant role in the process of Mitral Annular Calcification (MAC) as prognostic markers of calcific cardiac valves.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with diagnosis of MAC and patients coming to the Valve Clinic without MAC diagnosis Patients who will undergo surgery, either standard surgical MVR or trans-atrial TMVR, with diagnosis of MAC or without diagnosis of MAC

排除标准

  • Subjects unwilling to participate or to provide consent

结局指标

主要结局

Prognostic markers of calcific cardiac valves

时间窗: Baseline

Measured by Endothelial Progenitor Cells osteoblastic phenotype (EPC-OCNs) in Mitral Annular Calcification (MAC)

次要结局

未报告次要终点

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Amir Lerman

Principal Investigator

Mayo Clinic

研究点 (1)

Loading locations...

相似试验